REVELATION BIOSCIENCES, INC.(REVB)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
REVB Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for REVELATION BIOSCIENCES, INC. (REVB), a Healthcare sector company. REVB is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), REVELATION BIOSCIENCES, INC. reports net income of $-3.3M, free cash flow of $-2.6M. Top institutional holders of REVB by reported 13-F value include SABBY MANAGEMENT, CITADEL ADVISORS, GEODE CAPITAL MANAGEMENT, based on the most recent SEC filings. REVB trades on the Nasdaq exchange and files with the SEC under CIK 1810560. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate REVB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for REVELATION BIOSCIENCES, INC. directly from SEC EDGAR.
Net Income
Q2 2026
$-3.3M
Free Cash Flow
Q2 2026
$-2.6M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
+40.7% YoYOperating Income
-13.7% YoYEPS (Diluted)
+97.7% YoYTotal Assets
+74.9% YoYOp. Cash Flow
+54.9% YoYFree Cash Flow
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-8.9M +40.7% | $-15.0M -12405.6% | $-120.3K +98.9% | $-10.8M +9.7% | $-12.0M -635.2% | $-1.6M |
| Operating Income | $-9.1M -13.7% | $-8.0M +7.9% | $-8.7M +20.3% | $-10.9M +9.1% | $-12.0M | — |
| EPS (Diluted) | $-23.95 +97.7% | $-1052.16 -1638778.5% | $-0.06 +78.3% | $-0.30 -250.9% | $-0.08 | — |
| Total Assets | $11.6M +74.9% | $6.6M -45.8% | $12.2M +121.9% | $5.5M +169.5% | $2.0M -97.2% | $74.2M |
| Operating Cash Flow | $-8.3M +54.9% | $-18.3M -151.4% | $-7.3M +35.1% | $-11.2M -1.2% | $-11.1M -5056.6% | $-215.1K |
| Free Cash Flow | — | $-18.3M | — | — | $-11.2M | — |
Get alerted when REVB's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for REVELATION BIOSCIENCES, INC. including:
Top Institutional Holders of REVB
SABBY MANAGEMENT, LLC
$216.9K210,582 shCITADEL ADVISORS LLC
$39.7K38,579 shGEODE CAPITAL MANAGEMENT, LLC
$17.7K17,192 shHRT FINANCIAL LP
$17.0K16,978 shVANGUARD FIDUCIARY TRUST CO
$13.5K13,127 shTower Research Capital LLC (TRC)
$6.7K6,528 shROYAL BANK OF CANADA
$1.0K747 shSBI Securities Co., Ltd.
$354.00344 shBARCLAYS PLC
$173.00168 shHARBOUR INVESTMENTS, INC.
$42.0041 sh
| Fund | Value | Shares |
|---|---|---|
| SABBY MANAGEMENT, LLC | $216.9K | 210,582 |
| CITADEL ADVISORS LLC | $39.7K | 38,579 |
| GEODE CAPITAL MANAGEMENT, LLC | $17.7K | 17,192 |
| HRT FINANCIAL LP | $17.0K | 16,978 |
| VANGUARD FIDUCIARY TRUST CO | $13.5K | 13,127 |
| Tower Research Capital LLC (TRC) | $6.7K | 6,528 |
| ROYAL BANK OF CANADA | $1.0K | 747 |
| SBI Securities Co., Ltd. | $354.00 | 344 |
| BARCLAYS PLC | $173.00 | 168 |
| HARBOUR INVESTMENTS, INC. | $42.00 | 41 |
More Healthcare Companies
View all Healthcare →Put REVB on your watchlist
Track score changes the day REVELATION BIOSCIENCES, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is REVB a good stock to buy?
13F Pro's AI-powered analysis of REVELATION BIOSCIENCES, INC. (REVB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for REVB are available on the REVB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. REVB is classified as a small company.
Which hedge funds own REVB?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling REVB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of REVELATION BIOSCIENCES, INC.'s investment landscape.